Table 1 Characteristics of patients with SAPHO syndrome

Age, mean (SD), y

43.2 (12.3)

41.2 (8.6)

Male, n (%)

114 (30.3)

75 (37.3)

Married, n (%)

333 (88.6)

187 (93.0)

Smoking, n (%)

93 (24.7)

59 (29.4)

BMI, mean (SD)

23.7 (3.6)

23.8 (3.6)

VAS, n (%)

> 5

71

26

≤5

305

175

ESR (mm/h)

> 40

57

25

≤ 40

297

157

none

22

19

CRP (g/L)

>10

112

56

≤10

242

131

none

22

14

Disease duration, median (IQR), m

43.0 (22.0–72.0)

39.5 (18.0–72.0)

Education years, median (IQR), y

12.0 (10.0–15.0)

14.0 (12.0–16.0)

Anterior chest wall lesions, n (%)

354 (94.1)

192 (95.5)

Axial skeleton involvement, n (%)

233 (62.0)

115 (57.2)

Peripheral bone and joint involvement, n (%)

232 (61.7)

124 (61.7)

Cutaneous involvement, n (%)

330 (87.8)

180 (89.6)

Palmoplantar pustulosis, n (%)

294 (78.2)

159 (79.1)

Severe acne, n (%)

50 (13.3)

31 (15.4)

Psoriasis vulgaris, n (%)

78 (20.7)

45 (22.4)

Psoriatic nail disease, n (%)

80 (21.3)

45 (22.4)

VAS pain score, median (IQR)

3 (1–5)

3 (1–4)

PSQI, median (IQR)

9 (6–11)

8 (5–10)

CES-D, median (IQR)

10.5 (3–20)

8 (3–18)

FSS, median (IQR)

4.2 (2.4–5.9)

4.0 (2.3–5.3)

BASDAI, median (IQR)

2.2 (1.0-3.7)

1.8 (0.9–3.4)

BASFI, median (IQR)

0.6 (0.0-1.8)

0.4 (0.0-1.1)

EQ-5D, mean (SD)

0.74 (0.13)

0.76 (0.09)

HAQ-S, median (IQR)

0.04 (0.00-0.24)

0.00 (0.00-0.14)

ASQOL, median (IQR)

3 (3–8)

2 (0–7)

SF-36 PCS, median (IQR), %

42.5 (32.0-50.8)

45.1 (36.1–52.6)

SF-36 MCS, median (IQR), %

51.0 (41.7–61.8)

53.2 (42.9–62.6)

Absenteeism, median (IQR), %

NA

0 (0–13)

Presenteeism, median (IQR), %

NA

20 (0–40)

Work productivity loss, median (IQR), %

NA

20 (0–52)

Activity impairment, median (IQR), %

30 (0–50)

20 (20–40)